Physician profile
Christopher S Nickison
NPI 1962481465
$1,507.58
in general payments reported to CMS, 2019-2025
19 companies · $505 in 2025
The $505 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $35.95 · 2022: $44.39 · 2023: $406 · 2024: $391 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,302.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $382.97 | 2023-2025 | |
| Pfizer INC. | $186.04 | 2023-2025 | |
| Abbott Laboratories | $155.67 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Novo Nordisk INC | $132.21 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $125.00 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $99.44 | 2023-2024 | Rexulti, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $59.82 | 2025 | Auvelity, Symbravo |
| Lilly USA, LLC | $59.20 | 2023-2025 | Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $53.17 | 2023-2025 | Gvoke Hypopen |
| Dexcom, INC. | $39.71 | 2024-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $32.70 | 2023-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $29.28 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $27.26 | 2024-2025 | Airsupra |
| Phathom Pharmaceuticals, INC. | $27.25 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $25.99 | 2024 | Wavewriter Alpha Prime 16 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $23.54 | 2023 | Linq II |
| Glaxosmithkline, LLC. | $16.40 | 2023 | Arexvy, Shingrix |
| Currax Pharmaceuticals LLC | $15.98 | 2025 | Contrave |
| Inspire Medical Systems, INC. | $15.95 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Nickison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.